These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 6859457

  • 1. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S, Cossu P, Toccafondi C, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Loi A, Bertolino F, Cao A.
    Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
    [Abstract] [Full Text] [Related]

  • 2. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 3. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
    Flückiger A, Imbach P, Pfenninger E, Stocker F, Töndury P, Wagner HP, Weber J, Zuppinger K.
    Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
    [Abstract] [Full Text] [Related]

  • 4. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I, Hatzidimitriou-Papazacharia K, Spiliotopoulou J, Tsagarakis N, Digenopoulou E.
    Birth Defects Orig Artic Ser; 1988 Sep; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract] [Full Text] [Related]

  • 5. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD, Shurin SB, Nathan DG.
    N Engl J Med; 1976 Jun 24; 294(26):1421-3. PubMed ID: 1272274
    [Abstract] [Full Text] [Related]

  • 6. Iron overload and desferrioxamine chelation therapy in beta-thalassemia intermedia.
    Cossu P, Toccafondi C, Vardeu F, Sanna G, Frau F, Lobrano R, Cornacchia G, Nucaro A, Bertolino F, Loi A, De Virgiliis S, Cao A.
    Eur J Pediatr; 1981 Nov 24; 137(3):267-71. PubMed ID: 7318837
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Evaluation of iron overload in thalassemia].
    Piga A, Davico S, Magliano M, Luzzatto L, Sandri A, Gabutti V.
    Pediatr Med Chir; 1986 Nov 24; 8(1):9-13. PubMed ID: 3725619
    [Abstract] [Full Text] [Related]

  • 9. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Nov 24; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 10. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M, Galdo Capotorti M, Ponte G, Esposito L.
    Pediatria (Napoli); 1983 Nov 24; 91(4):371-7. PubMed ID: 6545400
    [No Abstract] [Full Text] [Related]

  • 11. Rubber band technique for slow subcutaneous infusion of desferrioxamine (Desferal).
    Hathirat P, Isarangkura P, Panthangkura W, Chuansumrit A, Sasanakul W, Kanasit R.
    Birth Defects Orig Artic Ser; 1988 Nov 24; 23(5B):123-7. PubMed ID: 3390534
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.
    Schettini F, Mautone A, Cavallo L, Altomare M, Montagna O, Dell'Edera L.
    Acta Haematol; 1981 Nov 24; 66(2):96-101. PubMed ID: 6794319
    [Abstract] [Full Text] [Related]

  • 14. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C, Rachmilewitz EA.
    Isr J Med Sci; 1978 Nov 24; 14(11):1111-5. PubMed ID: 750535
    [Abstract] [Full Text] [Related]

  • 15. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Nov 24; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV, Gorman A, Laulicht M, Garidi M, Economidou J, Georgipoulou P, Hussain MA, Flynn DM.
    Lancet; 1979 May 05; 1(8123):947-9. PubMed ID: 87616
    [Abstract] [Full Text] [Related]

  • 18. The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B.
    Bayraktar Y, Saglam F, Temizer A, Uzunalimodlu B, van Thiel DH.
    Hepatogastroenterology; 1998 May 05; 45(24):2322-7. PubMed ID: 9951916
    [Abstract] [Full Text] [Related]

  • 19. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.
    Fundam Clin Pharmacol; 2009 Jun 05; 23(3):359-65. PubMed ID: 19453758
    [Abstract] [Full Text] [Related]

  • 20. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 Jun 05; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.